Esbriet was rigorously analyzed in three phase 3 trials

Esbriet was evaluated in 1247 patients with IPF in three phase 3 trials 1

The efficacy of Esbriet was evaluated in three phase 3, randomized, double-blind, placebo-controlled, multicenter trials 1,3,4

  • Adult patients were enrolled who had a clinical and radiographic diagnosis of IPF (with or without accompanying surgical biopsy), without evidence or suspicion of an alternative diagnosis for interstitial lung disease 1
  • Study drug was administered with food in 3 equally divided doses and gradually increased to full dose over 2 weeks 3,4

 

Esbriet was studied across a range of patients with IPF

Clinical trials included patients with IPF with a range of clinical characteristics, select comorbidities, and concomitant medications 2

%FVC=percent predicted forced vital capacity; %DLco=percent predicted diffusing capacity of lung for carbon monoxide; FVC=forced vital capacity.
*Prevalence of comorbidities occurred in ≥15% of enrolled patients across all trials (N=1247).
Medications listed are commonly administered for select comorbidities.

 

EXPERT PERSPECTIVE:
EFFICACY AND SAFETY

Watch Steven Nathan, MD, discuss the clinical efficacy and safety of Esbriet

ESBRIET TABLETS    

Help your patients start and stay on Esbriet with 267 mg and 801 mg tablets 

ESBRIET SAFETY AND TOLERABILITY 

Learn more about the safety and tolerability profile of Esbriet